Alembic Pharmaceuticals Receives USFDA Final Approval for Tretinoin Cream USP, 0.025%

Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tretinoin Cream USP, 0.025%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025%, of Bausch Health US, LLC. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. The product has an estimated market size of US$ 94 million for twelve months ending June 2025 according to IQVIA. Alembic has a cumulative total of 224 ANDA approvals (202 final approvals and 22 tentative approvals).